Advances in biomarker research for pancreatic cancer

Current Pharmaceutical Design

Volumn 18, Issue 17, 2012, Pages 2439-2451

  Bhat, Kruttika ^a   Wang, Fengfei ^a   Ma, Qingyong ^b   Li, Qinyu ^c   Mallik, Sanku ^a   Hsieh, Tze chen ^d   Wu, Erxi ^a  

^a NORTH DAKOTA STATE UNIVERSITY   (United States)

^b THE FIRST AFFILIATED HOSPITAL OF XI AN JIAOTONG UNIVERSITY   (China)

^c SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^d NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Biomarker; CA 19 9; Pancreatic cancer; Risk factor; Tumor progression

Indexed keywords

BIOLOGICAL MARKER; BRCA2 PROTEIN; CA 125 ANTIGEN; CA 19-9 ANTIGEN; CA 242 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CARCINOEMBRYONIC ANTIGEN RELATED CELL ADHESION MOLECULE 1; CISPLATIN; CYCLIN D2; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DNA; ERLOTINIB; FANCONI ANEMIA GROUP C PROTEIN; FORKHEAD TRANSCRIPTION FACTOR; GEMCITABINE; HISTONE H3; K RAS PROTEIN; MICRORNA; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; OXALIPLATIN; PLACENTA PROTEIN 5; PROTEIN BAX; PROTEIN KINASE B BETA; PROTEIN KINASE LKB1; PROTEIN MLH1; PROTEIN P53; RNA; SECRETED FRIZZLED RELATED PROTEIN 1; SMAD4 PROTEIN; TISSUE FACTOR PATHWAY INHIBITOR;

ARTICLE; ASPIRATION BIOPSY; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER RELAPSE; CANCER STEM CELL; CANCER SURGERY; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; DEATH; DNA METHYLATION; ENDOSCOPIC ECHOGRAPHY; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; GEL ELECTROPHORESIS; GENE; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNORADIOMETRIC ASSAY; MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MORTALITY; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOGENE; PANCREAS BIOPSY; PANCREAS CANCER; PANCREAS SURGERY; POLYMERASE CHAIN REACTION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RISK FACTOR; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; SURVIVAL RATE; TANDEM MASS SPECTROMETRY; TISSUE MICROARRAY; TUMOR GROWTH; ULTRASOUND; UNITED STATES; WESTERN BLOTTING;

EID: 84860434801     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128112092439     Document Type: Article

References (269)

1. Chakraborty S, Baine MJ, Sasson AR, Batra SK. Current status of molecular markers for early detection of sporadic pancreatic cancer. Biochim Biophys Acta 2011; 1815(1): 44-64.
2. Verma M. Pancreatic Cancer Biomarkers and Their Implication in Cancer Diagnosis and Epidemiology. Cancers 2010; 2: 1830-7.
3. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61(4): 212-36.
4. Fry LC, Monkemuller K, Malfertheiner P. Molecular markers of pancreatic cancer: development and clinical relevance. Langenbecks Arch Surg 2008; 393: 883-90.
5. Jimeno A, Hidalgo M. Molecular biomarkers: their increasing role in the diagnosis, characterization, and therapy guidance in pancreatic cancer. Mol Cancer Ther 2006; 5: 787-96.
6. Strimpakos AS, Syrigos KN, Saif MW. Translational research in pancreatic cancer. Highlights from the "2010 ASCO Gastrointestinal Cancers Symposium". Orlando, FL, USA January 22-24, 2010. JOP; 11: 124-7.
7. Stathis A, Moore MJ. Advanced pancreatic carcinoma: current treatment and future challenges. Nat Rev Clin Oncol 2010; 7: 163-72.
8. Holly EA, Chaliha I, Bracci PM, Gautam M. Signs and symptoms of pancreatic cancer: a population-based case-control study in the San Francisco Bay area. Clin Gastroenterol Hepatol 2004; 2: 510-7.
9. Schmassmann A. [Pancreatic carcinoma: conservative and adjuvant therapy]. Ther Umsch 1996; 53: 387-93.
10. Isozaki H, Okajima K, Morita S, et al. Review of pancreatic cancer. Bull Osaka Med Coll 1990; 36: 1-11.
11. Costamagna G, Cotroneo AR, Mutignani M, Di Stasi C, Perri V. Carcinoma of the pancreatic head area. Therapy: nonoperative biliary drainage for palliation. Rays 1995; 20: 326-37.
12. el-Kamar FG, Grossbard ML, Kozuch PS. Metastatic pancreatic cancer: emerging strategies in chemotherapy and palliative care. Oncologist 2003; 8: 18-34.
13. Robinson PA. The role of MRI in pancreatic cancer. Eur Radiol 2002; 12: 267-9.
14. Stroszczynski C, Grutzmann R, Kittner T. CT and MR imaging of pancreatic cancer. Recent Results Cancer Res 2008; 177: 5-14.
15. Ardengh JC, de Paulo GA, Ferrari AP. Pancreatic carcinomas smaller than 3.0 cm: endosonography (EUS) in diagnosis, staging and prediction of resectability. HPB (Oxford) 2003; 5: 226-30.
16. Klapman J, Malafa MP. Early detection of pancreatic cancer: why, who, and how to screen. Cancer Control 2008; 15: 280-7.
17. Serrano OK, Chaudhry MA, Leach SD. The role of PET scanning in pancreatic cancer. Adv Surg 2010; 44: 313-25.
18. Adamek HE, Albert J, Breer H, Weitz M, Schilling D, Riemann JF. Pancreatic cancer detection with magnetic resonance cholangiopancreatography and endoscopic retrograde cholangiopancreatography: a prospective controlled study. Lancet 2000; 356: 190-3.
19. Erickson RA. ERCP and pancreatic cancer. Annals of Surgical Oncology 2004; 11: 555-7.
20. Ku YM, Shin SS, Lee CH, Semelka RC. Magnetic resonance imaging of cystic and endocrine pancreatic neoplasms. Top Magn Reson Imaging 2009; 20: 11-8.
21. Bournet B, Souque A, Senesse P, et al. Endoscopic ultrasoundguided fine-needle aspiration biopsy coupled with KRAS mutation assay to distinguish pancreatic cancer from pseudotumoral chronic pancreatitis. Endoscopy 2009; 41: 552-7.
22. Salek C, Benesova L, Zavoral M, et al. Evaluation of clinical relevance of examining K-ras, p16 and p53 mutations along with allelic losses at 9p and 18q in EUS-guided fine needle aspiration samples of patients with chronic pancreatitis and pancreatic cancer. World J Gastroenterol 2007; 13: 3714-20.
23. American gastroenterological association medical position statement: epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma. Gastroenterology 1999; 117: 1463-84.
24. Pitt HA. Curative treatment for pancreatic neoplasms. Standard resection. Surg Clin North Am 1995; 75: 891-904.
25. Wray CJ, Ahmad SA, Matthews JB, Lowy AM. Surgery for pancreatic cancer: recent controversies and current practice. Gastroenterology 2005; 128: 1626-41.
26. Zervos EE, Rosemurgy AS, Al-Saif O, Durkin AJ. Surgical management of early-stage pancreatic cancer. Cancer Control 2004; 11: 23-31.
27. Heinemann V. Gemcitabine: progress in the treatment of pancreatic cancer. Oncology 2001; 60: 8-18.
28. Mamon HJ, Niedzwiecki D, Hollis D, et al. A phase 2 trial of gemcitabine, 5-florouracil, and radiation therapy in locally advanced nonmetastatic pancreatic adenocarcinoma: cancer and Leukemia Group B (CALGB) 80003. Cancer. 2010; 117: 2620-8
29. Kim MP, Gallick GE. Gemcitabine resistance in pancreatic cancer: picking the key players. Clin Cancer Res 2008; 14: 1284-5.
30. Hidalgo M. Pancreatic cancer. N Engl J Med 2010; 362: 1605-17.
31. Hazard L. The role of radiation therapy in pancreas cancer. Gastrointest Cancer Res 2009; 3: 20-8.
32. Le Scodan R, Mornex F, Girard N, et al. Preoperative chemoradiation in potentially resectable pancreatic adenocarcinoma: feasibility, treatment effect evaluation and prognostic factors, analysis of the SFRO-FFCD 9704 trial and literature review. Ann Oncol 2009; 20: 1387-96.
33. Cooke EW, Hazard L. Curative radiation therapy for pancreatic malignancies. Surg Clin North Am 2010; 90: 341-54.
34. Lowenfels AB, Maisonneuve P. Epidemiology and risk factors for pancreatic cancer. Best Pract Res Clin Gastroenterol 2006; 20: 197-209.
35. Lowenfels AB, Maisonneuve P. Risk factors for pancreatic cancer. J Cell Biochem 2005; 95: 649-56.
36. Morse DL, Balagurunathan Y, Hostetter G, et al. Identification of novel pancreatic adenocarcinoma cell-surface targets by gene expression profiling and tissue microarray. Biochem Pharmacol 2010; 80: 748-54.
37. Takayama R, Nakagawa H, Sawaki A, et al. Serum tumor antigen REG4 as a diagnostic biomarker in pancreatic ductal adenocarcinoma. J Gastroenterol 2010; 45: 52-9.
38. Talamini G, Bassi C, Falconi M, et al. Alcohol and smoking as risk factors in chronic pancreatitis and pancreatic cancer. Digestive Diseases Sci 1999; 44: 1303-11.
39. Harada T, Chelala C, Bhakta V, et al. Genome-wide DNA copy number analysis in pancreatic cancer using high-density single nucleotide polymorphism arrays. Oncogene 2008; 27: 1951-60.
40. Bardeesy N, DePinho RA. Pancreatic cancer biology and genetics. Nat Rev Cancer 2002; 2: 897-909.
41. Ryu JK, Hong SM, Karikari CA, Hruban RH, Goggins MG, Maitra A. Aberrant MicroRNA-155 expression is an early event in the multistep progression of pancreatic adenocarcinoma. Pancreatology 2010; 10: 66-73.
42. Klimstra DS, Longnecker DS. K-ras mutations in pancreatic ductal proliferative lesions. Am J Pathol 1994; 145: 1547-50.
43. Pellegata NS, Sessa F, Renault B, et al. K-ras and p53 gene mutations in pancreatic cancer: ductal and nonductal tumors progress through different genetic lesions. Cancer Res 1994; 54: 1556-60.
44. Ghaneh P, Costello E, Neoptolemos JP. Biology and management of pancreatic cancer. Postgrad Med J 2008; 84: 478-97.
45. Fukushima N, Sato N, Ueki T, et al. Aberrant methylation of preproenkephalin and p16 genes in pancreatic Intraepithelial neoplasia and pancreatic ductal adenocarcinoma. Am J Pathol 2002; 160: 1573-81.
46. Ueki T, Toyota M, Skinner H, et al. Identification and characterization of differentially methylated CpG islands in pancreatic carcinoma. Cancer Res 2001; 61: 8540-6.
47. Korc M, Chandrasekar B, Yamanaka Y, Friess H, Buchier M, Beger HG. Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increases in the levels of epidermal growth factor and transforming growth factor alpha. J Clin Invest 1992; 90: 1352-60.
48. Barton CM, Hall PA, Hughes CM, Gullick WJ, Lemoine NR. Transforming growth factor alpha and epidermal growth factor in human pancreatic cancer. J Pathol 1991; 163: 111-6.
49. Friess H, Berberat P, Schilling M, Kunz J, Korc M, Buchler MW. Pancreatic cancer: the potential clinical relevance of alterations in growth factors and their receptors. J Mol Med 1996; 74: 35-42.
50. Simeone DM, Ji B, Banerjee M, et al. CEACAM1, a novel serum biomarker for pancreatic cancer. Pancreas 2007; 34: 436-43.
51. Schutte M, Hruban RH, Geradts J, et al. Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. Cancer Res 1997; 57: 3126-30.
52. Yamano M, Fujii H, Takagaki T, Kadowaki N, Watanabe H, Shirai T. Genetic progression and divergence in pancreatic carcinoma. Am J Pathol 2000; 156: 2123-33.
53. Boschman CR, Stryker S, Reddy JK, Rao MS. Expression of P53 Protein in Precursor Lesions and Adenocarcinoma of Human Pancreas. Am J Pathol 1994; 145: 1291-5.
54. Zindy F, Quelle DE, Roussel MF, Sherr CJ. Expression of the p16(INK4a) tumor suppressor versus other INK4 family members during mouse development and aging. Oncogene 1997; 15: 203-11.
55. Liu L, Dilworth D, Gao LZ, et al. Mutation of the CDKN2A 5 ' UTR creates an aberrant initiation codon and predisposes to melanoma. Nat Genetics 1999; 21: 128-32.
56. DiGiuseppe JA, Hruban RH, Goodman SN, et al. Overexpression of p53 protein in adenocarcinoma of the pancreas. Am J Clin Pathol 1994; 101: 684-8.
57. Goggins M, Hruban RH, Kern SE. BRCA2 is inactivated late in the development of pancreatic intraepithelial neoplasia - Evidence and implications. Am J Pathol 2000; 156: 1767-71.
58. Wilentz RE, Iacobuzio-Donahue CA, Argani P, et al. Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia: Evidence that DPC4 inactivation occurs late in neoplastic progression. Cancer Res 2000; 60: 2002-6.
59. Asomaning K, Reid AE, Zhou W, et al. MDM2 promoter polymorphism and pancreatic cancer risk and prognosis. Clinical Cancer Res 2008; 14: 4010-5.
60. Dong M, Ma G, Tu W, Guo KJ, Tian YL, Dong YT. Clinicopathological significance of p53 and mdm2 protein expression in human pancreatic cancer. World J Gastroenterol 2005; 11: 2162-5.
61. Wehler T, Wolfert F, Schimanski CC, et al. Strong expression of chemokine receptor CXCR4 by pancreatic cancer correlates with advanced disease. Oncology Reports 2006; 16: 1159-64.
62. Thomas RM, Kim J, Revelo-Penafiel MP, Angel R, Dawson DW, Lowy AM. The chemokine receptor CXCR4 is expressed in pancreatic intraepithelial neoplasia. Gut 2008; 57: 1555-60.
63. Thomas RM, Toney K, Fenoglio-Preiser C, et al. The RON receptor tyrosine kinase mediates oncogenic phenotypes in pancreatic cancer cells and is increasingly expressed during pancreatic cancer progression. Cancer Res 2007; 67: 6075-82.
64. Sato N, Fukushima N, Maitra A, et al. Discovery of novel targets for aberrant methylation in pancreatic carcinoma using highthroughput microarrays. Cancer Res 2003; 63: 3735-42.
65. Selaru FM, David S, Meltzer SJ, Hamilton JP. Epigenetic Events in Gastrointestinal Cancer. Am J Gastroenterol 2009; 104: 1910-2.
66. Koorstra JBM, Feldmann G, Habbe N, Maitra A. Morphogenesis of pancreatic cancer: role of pancreatic intraepithelial neoplasia (PanINs). Langenbecks Archives Surgery 2008; 393: 561-70.
67. van Heek NT, Meeker AK, Kern SE, et al. Telomere shortening is nearly universal in pancreatic intraepithelial neoplasia. Am J Pathol 2002; 161: 1541-7.
68. Gisselsson D, Jonson T, Petersen A, et al. Telomere dysfunction triggers extensive DNA fragmentation and evolution of complex chromosome abnormalities in human malignant tumors. Proceed Nat Academy Sci USA 2001; 98: 12683-8.
69. Lopez-Casas PP, Lopez-Fernandez LA. Gene-expression profiling in pancreatic cancer. Expert Rev Mol Diagn 2010; 10: 591-601.
70. Laurell H, Bouisson M, Berthelemy P, et al. Identification of biomarkers of human pancreatic adenocarcinomas by expression profiling and validation with gene expression analysis in endoscopic ultrasound-guided fine needle aspiration samples. World J Gastroenterol 2006; 12: 3344-51.
71. Liang JJ, Kimchi ET, Staveley-O'Carroll KF, Tan D. Diagnostic and prognostic biomarkers in pancreatic carcinoma. Int J Clin Exp Pathol 2009; 2: 1-10.
72. Gao J, Zhu F, Lv S, Li Z, Ling Z, Gong Y, et al. Identification of pancreatic juice proteins as biomarkers of pancreatic cancer. Oncol Rep 2010; 23: 1683-92.
73. Iacobuzio-Donahue CA, Maitra A, Olsen M, et al. Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarrays. Am J Pathol 2003; 162: 1151-62.
74. Wong SCC, Chan CML, Ma BBY, et al. Advanced proteomic technologies for cancer biomarker discovery. Expert Rev Proteomics 2009; 6: 123-34.
75. Ma N, Ge C-l, Luan F-m, et al. Serum protein fingerprint of patients with pancreatic cancer by SELDI technology. Chinese J Cancer Res 2008; 20: 171-6.
76. Xue A, Scarlett CJ, Chung L, et al. Discovery of serum biomarkers for pancreatic adenocarcinoma using proteomic analysis. British J Cancer 2010; 103: 391-400.
77. Yu KH, Rustgi AK, Blair IA. Characterization of proteins in human pancreatic cancer serum using differential gel electrophoresis and tandem mass spectrometry. J Proteome Res 2005; 4: 1742-51.
78. Tambor V, Fucikova A, Lenco J, et al. Application of Proteomics in Biomarker Discovery: a Primer for the Clinician. Physiological Res 2010; 59: 471-97.
79. Chen R, Pan S, Yi EC, et al. Quantitative proteomic profiling of pancreatic cancer juice. Proteomics 2006; 6: 3871-9.
80. Zhang L, Farrell JJ, Zhou H, et al. Salivary transcriptomic biomarkers for detection of resectable pancreatic cancer. Gastroenterology 2010; 138: 949-57 e1-7.
81. Haug U, Wente MN, Seiler CM, Jesnowski R, Brenner H. Stool testing for the early detection of pancreatic cancer: rationale and current evidence. Expert Rev Mol Diagn 2008; 8: 753-9.
82. Brody JR, Costantino CL, Potoczek M, et al. Adenosquamous carcinoma of the pancreas harbors KRAS2, DPC4 and TP53 molecular alterations similar to pancreatic ductal adenocarcinoma. Mod Pathol 2009; 22: 651-9.
83. Liu F. SMAD4/DPC4 and pancreatic cancer survival. Commentary re: M. Tascilar et al., The SMAD4 protein and prognosis of pancreatic ductal adenocarcinoma. Clin Cancer Res 7: 4115-4121, 2001. Clin Cancer Res 2001; 7: 3853-6.
84. Biankin AV, Morey AL, Lee CS, et al. DPC4/Smad4 expression and outcome in pancreatic ductal adenocarcinoma. J Clin Oncol 2002; 20: 4531-42.
85. Gu LJ, Chen J, Lu ZH, Li L, Zhou WX, Luo YF. [Expression of DPC4/Smad4, p21wafI, and p16 in human pancreatic cancer]. Ai Zheng 2002; 21: 132-7.
86. Kipp BR, Fritcher EG, Clayton AC, et al. Comparison of KRAS mutation analysis and FISH for detecting pancreatobiliary tract cancer in cytology specimens collected during endoscopic retrograde cholangiopancreatography. J Mol Diagn 2010; 12: 780-6.
87. Wu X, Lu XH, Xu T, et al. Evaluation of the diagnostic value of serum tumor markers, and fecal k-ras and p53 gene mutations for pancreatic cancer. Chin J Dig Dis 2006; 7: 170-4.
88. Zinsky R, Bolukbas S, Bartsch H, Schirren J, Fisseler-Eckhoff A. Analysis of KRAS Mutations of Exon 2 Codons 12 and 13 by SNaPshot Analysis in Comparison to Common DNA Sequencing. Gastroenterol Res Pract; 2010: 789363.
89. Morton JP, Timpson P, Karim SA, et al. Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer. Proc Natl Acad Sci USA 2009; 107: 246-51.
90. Jeong J, Park YN, Park JS, Yoon DS, Chi HS, Kim BR. Clinical significance of p16 protein expression loss and aberrant p53 protein expression in pancreatic cancer. Yonsei Med J 2005; 46: 519-25.
91. Gerdes B, Ramaswamy A, Kersting M, et al. p16(INK4a) alterations in chronic pancreatitis-indicator for high-risk lesions for pancreatic cancer. Surgery 2001; 129: 490-7.
92. Maitra A, Molberg K, Albores-Saavedra J, Lindberg G. Loss of Dpc4 expression in colonic adenocarcinomas correlates with the presence of metastatic disease. Am J Pathol 2000; 157: 1105-11.
93. Iacobuzio-Donahue CA, Fu B, Yachida S, et al. DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol 2009; 27: 1806-13.
94. Maitra A, Kern SE, Hruban RH. Molecular pathogenesis of pancreatic cancer. Best Pract Res Clin Gastroenterol 2006; 20: 211-26.
95. Jiang Y, Mackley H, Cheng H, Ajani JA. Use of K-Ras as a predictive biomarker for selecting anti-EGF receptor/pathway treatment. Biomark Med 2010; 4: 535-41.
96. Morris JP, Wang SC, Hebrok M. KRAS, Hedgehog, Wnt and the twisted developmental biology of pancreatic ductal adenocarcinoma. Nature Rev Cancer 2010; 10: 683-95.
97. Rustgi AK. The molecular pathogenesis of pancreatic cancer: clarifying a complex circuitry. Genes & Development 2006; 20: 3049-53.
98. Slater EP, Langer P, Fendrich V, et al. Prevalence of BRCA2 and CDKN2a mutations in German familial pancreatic cancer families. Fam Cancer 2010; 9: 335-43.
99. Matsubayashi H, Canto M, Sato N, et al. DNA methylation alterations in the pancreatic juice of patients with suspected pancreatic disease. Cancer Res 2006; 66: 1208-17.
100. Bausch D, Thomas S, Mino-Kenudson M, et al. Plectin-1 as a novel biomarker for pancreatic cancer. Clin Cancer Res 2010; 17:302-9.
101. Balasenthil S, Chen N, Lott ST, et al. A migration signature and plasma biomarker panel for pancreatic adenocarcinoma. Cancer Prev Res (Phila) 2010; 4: 137-49.
102. Kurtova A, Sivina M, Quiroga MP, Wierda WG, Keating MJ, Burger JA. The Immunophenotype Signature CD49d(+)CD38(+) Identifies Chronic Lymphocytic Leukemia Cases with a Higher Potential for Migration Beneath Marrow Stromal Cells. Blood 2009; 114: 150-1.
103. Sakorafas GH, Tsiotou AG, Tsiotos GG. Molecular biology of pancreatic cancer; oncogenes, tumour suppressor genes, growth factors, and their receptors from a clinical perspective. Cancer Treat Rev 2000; 26: 29-52.
104. Mulero-Navarro S, Esteller M. Epigenetic biomarkers for human cancer: The time is now. Critical Rev Oncol Hematol 2008; 68: 1-11.
105. Tan AC, Jimeno A, Lin SH, et al. Characterizing DNA methylation patterns in pancreatic cancer genome. Molecular Oncology 2009; 3: 425-38.
106. Omura N, Li CP, Li A, et al. Genome-wide profiling of methylated promoters in pancreatic adenocarcinoma. Cancer Biol Therapy 2008; 7: 1146-56.
107. Ohtsubo K, Watanabe H, Yao F, et al. Preproenkephalin hypermethylation in the pure pancreatic juice compared with p53 mutation in the diagnosis of pancreatic carcinoma. J Gastroenterol 2006; 41: 791-7.
108. Shimizu K, Itsuzaki Y, Fujii H, Honoki K, Tsujiuchi T. Reduced expression of the Rassf1a gene and its aberrant DNA methylation in pancreatic duct adenocarcinomas induced by N-nitrosobis(2- oxopropyl)amine in hamsters. Mol Carcinog 2008; 47: 80-7.
109. Pizzi S, Azzoni C, Bottarelli L, et al. RASSF1A promoter methylation and 3p21.3 loss of heterozygosity are features of foregut, but not midgut and hindgut, malignant endocrine tumours. J Pathol 2005; 206: 409-16.
110. House MG, Herman JG, Guo MZ, et al. Aberrant hypermethylation of tumor suppressor genes in pancreatic endocrine neoplasms. Ann Surg 2003; 238: 423-31; discussion 31-2.
111. Dammann R, Schagdarsurengin U, Liu LM, et al. Frequent RASSF1A promoter hypermethylation and K-ras mutations in pancreatic carcinoma. Oncogene 2003; 22: 3806-12.
112. Matsubayashi H, Sato N, Fukushima N, et al. Methylation of cyclin D2 is observed frequently in pancreatic cancer but is also an agerelated phenomenon in gastrointestinal tissues. Clin Cancer Res 2003; 9: 1446-52.
113. Virmani A, Rathi A, Heda S, et al. Aberrant methylation of the Cyclin D2 promoter in primary small cell, nonsmall cell lung and breast cancers. Int J Cancer 2003; 107: 341-5.
114. Sakai M, Hibi K, Koshikawa K, et al. Frequent promoter methylation and gene silencing of CDH13 in pancreatic cancer. Cancer Sci 2004; 95: 588-91.
115. Watanabe H, Okada G, Ohtsubo K, et al. Aberrant methylation of secreted apoptosis-related protein 2 (SARP2) in pure pancreatic juice in diagnosis of pancreatic neoplasms. Pancreas 2006; 32: 382-9.
116. Park JK, Ryu JK, Lee KH, et al. Quantitative analysis of NPTX2 hypermethylation is a promising molecular diagnostic marker for pancreatic cancer. Pancreas 2007; 35: e9-15.
117. Melnikov AA, Scholtens D, Talamonti MS, Bentrem DJ, Levenson VV. Methylation Profile of Circulating Plasma DNA in Patients With Pancreatic Cancer. J Surgical Oncol 2009; 99: 119-22.
118. Manuyakorn A, Paulus R, Farrell J, et al. Cellular Histone Modification Patterns Predict Prognosis and Treatment Response in Resectable Pancreatic Adenocarcinoma: Results From RTOG 9704. J Clinical Oncol 2010; 28: 1358-65.
119. Li A, Omura N, Hong SM, et al. Pancreatic cancers epigenetically silence SIP1 and hypomethylate and overexpress miR-200a/200b in association with elevated circulating miR-200a and miR-200b levels. Cancer Res 2010; 70: 5226-37.
120. Nimmo RA, Slack FJ. An elegant miRror: microRNAs in stem cells, developmental timing and cancer. Chromosoma 2009; 118: 405-18.
121. Croce CM. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet 2009; 10: 704-14.
122. Rosenfeld N, Aharonov R, Meiri E, et al. MicroRNAs accurately identify cancer tissue origin. Nat Biotechnol 2008; 26: 462-9.
123. Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 2006; 6: 259-69.
124. Bartels CL, Tsongalis GJ. [MicroRNAs: novel biomarkers for human cancer]. Ann Biol Clin (Paris) 2009; 68: 263-72.
125. Szafranska AE, Davison TS, John J, et al. MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma. Oncogene 2007; 26: 4442-52.
126. Kong X, Du Y, Wang G, et al. Erratum to: Detection of Differentially Expressed microRNAs in Serum of Pancreatic Ductal Adenocarcinoma Patients: miR-196a Could Be a Potential Marker for Poor Prognosis. Dig Dis Sci 2011; 56: 602-9.
127. Ho AS, Huang X, Cao H, et al. Circulating miR-210 as a Novel Hypoxia Marker in Pancreatic Cancer. Transl Oncol 2010; 3: 109-13.
128. Giovannetti E, Funel N, Peters GJ, et al. MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity. Cancer Res 2010; 70: 4528-38.
129. Hwang J-H, Voortman J, Giovannetti E, et al. Identification of MicroRNA-21 as a Biomarker for Chemoresistance and Clinical Outcome Following Adjuvant Therapy in Resectable Pancreatic Cancer. PLoS One 2010; 5: e10630.
130. du Rieu MC, Torrisani J, Selves J, et al. MicroRNA-21 is induced early in pancreatic ductal adenocarcinoma precursor lesions. Clin Chem 2010; 56: 603-12.
131. Zhang Y, Li M, Wang H, et al. Profiling of 95 microRNAs in pancreatic cancer cell lines and surgical specimens by real-time PCR analysis. World J Surg 2009; 33: 698-709.
132. Haas M, Laubender RP, Stieber P, et al. Prognostic relevance of CA 19-9, CEA, CRP, and LDH kinetics in patients treated with palliative second-line therapy for advanced pancreatic cancer. Tumour Biol 2010; 31: 351-7.
133. Ho JJ, Siddiki B, Kim YS. Association of sialyl-Lewis(a) and sialyl-Lewis(x) with MUC-1 apomucin ina pancreatic cancer cell line. Cancer Res 1995; 55: 3659-63.
134. Steinberg W. The clinical utility of the CA 19-9 tumor-associated antigen. Am J Gastroenterol 1990; 85: 350-5.
135. Andren-Sandberg A. CA 50 and CA 19-9 in serum as tumor markers for pancreatic cancer: a review of the literature. Acta Chir Scand Suppl 1989; 549: 75-81.
136. Kokhanenko N, Ignashov AM, Varga EV, et al. [Role of the tumor markers CA 19-9 and carcinoembryonic antigen (CEA) in diagnosis, treatment and prognosis of pancreatic cancer]. Vopr Onkol 2001; 47: 294-7.
137. Baeckstrom D, Hansson GC, Nilsson O, Johansson C, Gendler SJ, Lindholm L. Purification and characterization of a membranebound and a secreted mucin-type glycoprotein carrying the carcinoma-associated sialyl-Lea epitope on distinct core proteins. J Biol Chem 1991; 266: 21537-47.
138. Koprowski H, Herlyn M, Steplewski Z, Sears HF. Specific antigen in serum of patients with colon carcinoma. Science 1981; 212: 53-5.
139. Koprowski H, Steplewski Z, Mitchell K, Herlyn M, Herlyn D, Fuhrer P. Colorectal carcinoma antigens detected by hybridoma antibodies. Somatic Cell Genet 1979; 5: 957-71.
140. Magnani JL, Nilsson B, Brockhaus M, et al. A monoclonal antibody-defined antigen associated with gastrointestinal cancer is a ganglioside containing sialylated lacto-N-fucopentaose II. J Biol Chem 1982; 257: 14365-9.
141. Ugorski M, Laskowska A. Sialyl Lewis(a): a tumor-associated carbohydrate antigen involved in adhesion and metastatic potential of cancer cells. Acta Biochimica Polonica 2002; 49: 303-11.
142. Vestergaard EM, Hein HO, Meyer H, et al. Reference values and biological variation for tumor marker CA 19-9 in serum for different Lewis and secretor genotypes and evaluation of secretor and Lewis genotyping in a Caucasian population. Clin Chem 1999; 45: 54-61.
143. Hanisch FG, Uhlenbruck G, Dienst C. Structure of tumorassociated carbohydrate antigen Ca 19-9 on human seminal-plasma glycoproteins from healthy donors. Eur J Biochem 1984; 144: 467-73.
144. Tempero MA, Uchida E, Takasaki H, Burnett DA, Steplewski Z, Pour PM. Relationship of Carbohydrate Antigen 19-9 and Lewis Antigens in Pancreatic-Cancer. Cancer Research 1987; 47: 5501-3.
145. Eskelinen M, Haglund U. Developments in serologic detection of human pancreatic adenocarcinoma. Scand J Gastroenterol 1999; 34: 833-44.
146. Sreejayan N, Wittig BM, Von Stillfried N, et al. Human biliary mucin binds to E-selectin: a possible role in modulation of inflammation. Am J Physiology-Gastrointestinal Liver Physiol 2001; 280: G1043-G8.
147. Kannagi R. Carbohydrate antigen sialyl Lewis a--its pathophysiological significance and induction mechanism in cancer progression. Chang Gung Med J 2007; 30: 189-209.
148. Miyazaki K, Ohmori K, Izawa M, et al. Loss of disialyl Lewis(a), the ligand for lymphocyte inhibitory receptor sialic acid-binding immunoglobulin-like lectin-7 (Siglec-7) associated with increased sialyl Lewis(a) expression on human colon cancers. Cancer Res 2004; 64: 4498-505.
149. Ritts RE, Delvillano BC, Go VLW, Herberman RB, Klug TL, Zurawski VR. Initial Clinical-Evaluation of an Immunoradiometric Assay for Ca-19-9 Using the Nci Serum Bank. Int J Cancer 1984; 33: 339-45.
150. Satake K, Kanazawa G, Kho I, Chung YS, Umeyama K. A Clinical-Evaluation of Carbohydrate Antigen 19-9 and Carcinoembryonic Antigen in Patients with Pancreatic-Carcinoma. J Surgical Oncol 1985; 29: 15-21.
151. Safi F, Beger HG, Bittner R, Buchler M, Krautzberger W. Ca-19-9 and Pancreatic Adenocarcinoma. Cancer 1986; 57: 779-83.
152. Duffy MJ, Sturgeon C, Lamerz R, et al. Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report. Ann Oncol 2010; 21: 441-7.
153. Tian FH, Appert HE, Myles J, Howard JM. Prognostic Value of Serum Ca-19-9 Levels in Pancreatic Adenocarcinoma. Annals Surgery 1992; 215: 350-5.
154. Glenn J, Steinberg WM, Kurtzman SH, Steinberg SM, Sindelar WF. Evaluation of the Utility of a Radioimmunoassay for Serum Ca-19-9 Levels in Patients before and after Treatment of Carcinoma of the Pancreas. J Clinical Oncol 1988; 6: 462-8.
155. Forsmark CE, Lambiase L, Vogel SB. Diagnosis of Pancreatic- Cancer and Prediction of Unresectability Using the Tumor- Associated Antigen Ca19-9. Pancreas 1994; 9: 731-4.
156. Lundin J, Roberts PJ, Kuusela P, Haglund C. The Prognostic Value of Preoperative Serum Levels of Ca-19-9 and Cea in Patients with Pancreatic-Cancer. British J Cancer 1994; 69: 515-9.
157. Willett CG, Daly WJ, Warshaw AL. CA 19-9 is an index of response to neoadjunctive chemoradiation therapy in pancreatic cancer. Am J Surgery 1996; 172: 350-2.
158. Goonetilleke KS, Siriwardena AK. Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Ejso 2007; 33: 266-70.
159. Gold DV, Modrak DE, Ying Z, Cardillo TM, Sharkey RM, Goldenberg DM. New MUC1 serum immunoassay differentiates pancreatic cancer from pancreatitis. J Clin Oncol 2006; 24: 252-8.
160. Tumour markers in gastrointestinal cancers--EGTM recommendations. European Group on Tumour Markers. Anticancer Res 1999; 19: 2811-5.
161. Szajda SD, Waszkiewicz N, Chojnowska S, Zwierz K. Carbohydrate markers of pancreatic cancer. Biochem Soc Trans 2011; 39: 340-3.
162. Duffy MJ. CA 19-9 as a marker for gastrointestinal cancers: a review. Annals of Clinical Biochemistry 1998; 35: 364-70.
163. Lamerz R. Role of tumour markers, cytogenetics. Annals of Oncology 1999; 10: 145-9.
164. Monaghan PJ, Leonard MB, Neithercut WD, Raraty MGT, Sodi R. False positive carbohydrate antigen 19-9 (CA19-9) results due to a low-molecular weight interference in an apparently healthy male. Clinica Chimica Acta 2009; 406: 41-4.
165. Kuhlmann KF, van Till JW, Boermeester MA, et al. Evaluation of matrix metalloproteinase 7 in plasma and pancreatic juice as a biomarker for pancreatic cancer. Cancer Epidemiol Biomarkers Prev 2007; 16: 886-91.
166. Chen R, Pan S, Duan X, et al. Elevated level of anterior gradient-2 in pancreatic juice from patients with pre-malignant pancreatic neoplasia. Mol Cancer 2010; 9: 149.
167. Ohuchida K, Mizumoto K, Yu J, et al. S100A6 is increased in a stepwise manner during pancreatic carcinogenesis: clinical value of expression analysis in 98 pancreatic juice samples. Cancer Epidemiol Biomarkers Prev 2007; 16: 649-54.
168. Suehara N, Mizumoto K, Niiyama H, Tanaka M. [Specific activation of telomerase in pancreatic cancer tissue and preoperative diagnosis of pancreatic cancer by telomerase in pancreatic juice]. Nippon Rinsho 1998; 56: 1223-8.
169. Li J, Ma Q, Liu H, et al. Relationship between Neural Alteration and Perineural Invasion in Pancreatic Cancer Patients with Hyperglycemia. PLoS One 2011; 6: e17385.
170. Bunger S, Laubert T, Roblick UJ, Habermann JK. Serum biomarkers for improved diagnostic of pancreatic cancer: a current overview. J Cancer Research and Clinical Oncology 2011; 137: 375-89.
171. Brand RE, Nolen BM, Zeh HJ, et al. Serum Biomarker Panels for the Detection of Pancreatic Cancer. Clin Cancer Res 2011; 17: 805-16.
172. Hermann PC, Huber SL, Herrler T, et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007; 1: 313-23.
173. Sergeant G, Vankelecom H, Gremeaux L, Topal B. Role of cancer stem cells in pancreatic ductal adenocarcinoma. Nat Rev Clin Oncol 2009; 6: 580-6.
174. Bhagwandin VJ, Shay JW. Pancreatic cancer stem cells: fact or fiction? Biochim Biophys Acta 2009; 1792: 248-59.
175. Huang P, Wang CY, Gou SM, Wu HS, Liu T, Xiong JX. Isolation and biological analysis of tumor stem cells from pancreatic adenocarcinoma. World J Gastroenterol 2008; 14: 3903-7.
176. Toshio K, Itoi T, Sofuni A, et al. Detection of circulating tumor cells in patients with pancreatic carcinoma. Gastroenterology 2007; 132: A351-A.
177. Kurihara T, Itoi T, Sofuni A, et al. Detection of circulating tumor cells in patients with pancreatic cancer: a preliminary result. J Hepato-Biliary-Pancreatic Surgery 2008; 15: 189-95.
178. Klos D, Srovnal J, Lovecek M, Hajduch M, Neoral C, Havlik R. Determination of minimal residual disease in pancreatic cancer - clinical benefit. Br J Surgery 2010; 97: S69-S70.
179. An X, Ding PR, Li YH, et al. Elevated neutrophil to lymphocyte ratio predicts survival in advanced pancreatic cancer. Biomarkers 2010; 15: 516-22.
180. Chang P, Li Y, Li D. Micronuclei Levels in Peripheral Blood Lymphocytes as a Potential Biomarker for Pancreatic Cancer Risk. Carcinogenesis 2010; 32: 210-215.
181. Hoffmann K, Kerner C, Wilfert W, et al. Detection of disseminated pancreatic cells by amplification of cytokeratin-19 with quantitative RT-PCR in blood, bone marrow and peritoneal lavage of pancreatic carcinoma patients. World J Gastroenterol 2007; 13: 257-63.
182. Helmstaedter L, Riemann JF. Pancreatic cancer--EUS and early diagnosis. Langenbecks Arch Surg 2008; 393: 923-7.
183. Levy MJ, Wiersema MJ. Endoscopic ultrasound in the diagnosis and staging of pancreatic cancer. Oncology (Williston Park) 2002; 16: 29-38, 43; discussion 4, 7-9, 53-6.
184. Berberat P, Friess H, Kashiwagi M, Beger HG, Buchler MW. Diagnosis and staging of pancreatic cancer by positron emission tomography. World J Surg 1999; 23: 882-7.
185. Rocca R, De Angelis C, Daperno M, et al. Endoscopic ultrasoundfine needle aspiration (EUS-FNA) for pancreatic lesions: effectiveness in clinical practice. Dig Liver Dis 2007; 39: 768-74.
186. James TA, Gibbs JF. Pancreatic cancer screening: identifying premalignant disease. Future Oncol 2005; 1: 191-5.
187. Iqbal S, Stevens PD. Cholangiopancreatoscopy for targeted biopsies of the bile and pancreatic ducts. Gastrointest Endosc Clin N Am 2009; 19: 567-77.
188. Fleming JB, Gonzalez RJ, Petzel MQ, et al. Influence of obesity on cancer-related outcomes after pancreatectomy to treat pancreatic adenocarcinoma. Arch Surg 2009; 144: 216-21.
189. McWilliams RR, Matsumoto ME, Burch PA, et al. Obesity Adversely Affects Survival in Pancreatic Cancer Patients. Cancer 2010; 116: 5054-62.
190. Li DH, Morris JS, Liu J, et al. Body Mass Index and Risk, Age of Onset, and Survival in Patients With Pancreatic Cancer. Jama-J the Am Medical Association 2009; 301: 2553-62.
191. Jiao L, Hassan MM, Bondy ML, et al. XRCC2 and XRCC3 gene polymorphism and risk of pancreatic cancer. Am J Gastroenterol 2008; 103: 360-7.
192. Iodice S, Gandini S, Maisonneuve P, Lowenfels AB. Tobacco and the risk of pancreatic cancer: a review and meta-analysis. Langenbecks Arch Surg 2008; 393: 535-45.
193. Li D, Tang H, Hassan MM, Holly EA, Bracci PM, Silverman DT. Diabetes and risk of pancreatic cancer: a pooled analysis of three large case-control studies. Cancer Causes Control 2011; 22: 189-97.
194. Yalniz M, Pour PM. Diabetes mellitus: a risk factor for pancreatic cancer? Langenbecks Arch Surg 2005; 390: 66-72.
195. Whitcomb DC, Pogue-Geile K. Pancreatitis as a risk for pancreatic cancer. Gastroenterol Clinics North Am 2002; 31: 663-+.
196. Raimondi S, Lowenfels AB, Morselli-Labate AM, Maisonneuve P, Pezzilli R. Pancreatic cancer in chronic pancreatitis; aetiology, incidence, and early detection. Best Practice Res Clinical Gastroenterol 2010; 24: 349-58.
197. Latchford A, Greenhalf W, Vitone LJ, Neoptolemos JP, Lancaster GA, Phillips RK. Peutz-Jeghers syndrome and screening for pancreatic cancer. Br J Surg 2006; 93: 1446-55.
198. Klump B, Hsieh CJ, Nehls O, et al. Methylation status of p14ARF and p16INK4a as detected in pancreatic secretions. Br J Cancer 2003; 88: 217-22.
199. Wolpin BM, Chan AT, Hartge P, et al. ABO Blood Group and the Risk of Pancreatic Cancer. J National Cancer Institute 2009; 101: 424-31.
200. Wolpin BM, Kraft P, Gross M, et al. Pancreatic Cancer Risk and ABO Blood Group Alleles: Results from the Pancreatic Cancer Cohort Consortium. Cancer Res 2010; 70: 1015-23.
201. Greer JB, Yazer MH, Raval JS, Barmada MM, Brand RE, Whitcomb DC. Significant association between ABO blood group and pancreatic cancer. World J Gastroenterol 2010; 16: 5588-91.
202. Seibert V, Ebert MP, Buschmann T. Advances in clinical cancer proteomics: SELDI-ToF-mass spectrometry and biomarker discovery. Brief Funct Genomic Proteomic 2005; 4: 16-26.
203. Maurya P, Meleady P, Dowling P, Clynes M. Proteomic approaches for serum biomarker discovery in cancer. Anticancer Res 2007; 27: 1247-55.
204. Chen R, Pan S, Brentnall TA, Aebersold R. Proteomic profiling of pancreatic cancer for biomarker discovery. Mol Cell Proteomics 2005; 4: 523-33.
205. Mauri P, Scarpa A, Nascimbeni AC, et al. Identification of proteins released by pancreatic cancer cells by multidimensional protein identification technology: a strategy for identification of novel cancer markers. FASEB J 2005; 19: 1125-7.
206. Rong YF, Jin DY, Hou CR, et al. Proteomics analysis of serum protein profiling in pancreatic cancer patients by DIGE: upregulation of mannose-binding lectin 2 and myosin light chain kinase 2. Bmc Gastroenterol 2010; 10: -.
207. Chen R, Brentnall TA, Pan S, et al. Quantitative proteomics analysis reveals that proteins differentially expressed in chronic pancreatitis are also frequently involved in pancreatic cancer. Mol Cellular Proteomics 2007; 6: 1331-42.
208. Chen R, Yi EC, Donohoe S, et al. Pancreatic cancer proteome: the proteins that underlie invasion, metastasis, and immunologic escape. Gastroenterology 2005; 129: 1187-97.
209. Ehmann M, Felix K, Hartmann D, et al. Identification of potential markers for the detection of pancreatic cancer through comparative serum protein expression profiling. Pancreas 2007; 34: 205-14.
210. Ransohoff DF. Bias as a threat to the validity of cancer molecularmarker research. Nat Rev Cancer 2005; 5: 142-9.
211. Kruger M, Moser M, Ussar S, et al. SILAC mouse for quantitative proteomics uncovers kindlin-3 as an essential factor for red blood cell function. Cell 2008; 134: 353-64.
212. McDonald WH, Yates JR, 3rd. Shotgun proteomics and biomarker discovery. Dis Markers 2002; 18: 99-105.
213. Chen J, Li D, Killary AM, et al. Polymorphisms of p16, p27, p73, and MDM2 modulate response and survival of pancreatic cancer patients treated with preoperative chemoradiation. Ann Surg Oncol 2009; 16: 431-9.
214. Tanase CP, Dima S, Mihai M, et al. Caveolin-1 overexpression correlates with tumour progression markers in pancreatic ductal adenocarcinoma. J Molecular Histol 2009; 40: 23-9.
215. Giovannetti E, Del Tacca M, Mey V, et al. Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine. Cancer Res 2006; 66: 3928-35.
216. Szafranska AE, Doleshal M, Edmunds HS, et al. Analysis of microRNAs in pancreatic fine-needle aspirates can classify benign and malignant tissues. Clin Chem 2008; 54: 1716-24.
217. Chen BZ, Yu SL, Singh S, et al. Identification of microRNAs expressed highly in pancreatic islet-like cell clusters differentiated from human embryonic stem cells. Cell Biol Int 2011; 35: 29-37.
218. Greither T, Grochola LF, Udelnow A, Lautenschlager C, Wurl P, Taubert H. Elevated expression of microRNAs 155, 203, 210 and 222 in pancreatic tumors is associated with poorer survival. Int J Cancer 2010; 126: 73-80.
219. Li YW, VandenBoom TG, Kong DJ, et al. Up-regulation of miR-200 and let-7 by Natural Agents Leads to the Reversal of Epithelial-to-Mesenchymal Transition in Gemcitabine-Resistant Pancreatic Cancer Cells. Cancer Res 2009; 69: 6704-12.
220. Stratford JK, Bentrem DJ, Anderson JM, et al. A Six-Gene Signature Predicts Survival of Patients with Localized Pancreatic Ductal Adenocarcinoma. Plos Medicine 2010; 7: e1000307.
221. Ohuchida K, Mizumoto K, Ishikawa N, et al. The role of S100A6 in pancreatic cancer development and its clinical implication as a diagnostic marker and therapeutic target. Clin Cancer Res 2005; 11: 7785-93.
222. Tian M, Cui YZ, Song GH, et al. Proteomic analysis identifies MMP-9, DJ-1 and A1BG as overexpressed proteins in pancreatic juice from pancreatic ductal adenocarcinoma patients. BMC Cancer 2008; 8: 241.
223. Sadakari Y, Ohtsuka T, Ohuchida K, et al. MicroRNA expression analyses in preoperative pancreatic juice samples of pancreatic ductal adenocarcinoma. JOP 2010; 11: 587-92.
224. Habbe N, Koorstra JBM, Mendell JT, et al. MicroRNA miR-155 is a biomarker of early pancreatic neoplasia. Cancer Biol Therapy 2009; 8: 340-6.
225. Ohuchida K, Mizumoto K, Ohhashi S, et al. Twist, a novel oncogene, is upregulated in pancreatic cancer: clinical implication of Twist expression in pancreatic juice. Int J Cancer 2007; 120: 1634-40.
226. Nakashima A, Murakami Y, Uemura K, et al. Usefulness of Human Telomerase Reverse Transcriptase in Pancreatic Juice as a Biomarker of Pancreatic Malignancy. Pancreas 2009; 38: 527-33.
227. Satake K. Diagnosis of pancreatic cancer. Serological markers. Int J Pancreatol 1991; 9: 93-8.
228. Cappelli G, Paladini S, D'Agata A. Tumor markers in the diagnosis of pancreatic cancer. Tumori 1999; 85: S19-21.
229. Harmenberg U, Wahren B, Wiechel KL. Tumor markers carbohydrate antigens CA 19-9 and CA-50 and carcinoembryonic antigen in pancreatic cancer and benign diseases of the pancreatobiliary tract. Cancer Res 1988; 48: 1985-8.
230. Liao WC, Wu MS, Wang HP, Tien YW, Lin JT. Serum Heat Shock Protein 27 Is Increased in Chronic Pancreatitis and Pancreatic Carcinoma. Pancreas 2009; 38: 422-6.
231. Karna E, Surazynski A, Orlowski K, et al. Serum and tissue level of insulin-like growth factor-I (IGF-I) and IGF-I binding proteins as an index of pancreatitis and pancreatic cancer. Int J Exp Pathol 2002; 83: 239-45.
232. Sun ZL, Zhu Y, Wang FQ, et al. Serum proteomic-based analysis of pancreatic carcinoma for the identification of potential cancer biomarkers. Biochim Biophys Acta 2007; 1774: 764-71.
233. Abbasciano V, Graziano L, Guerra S, et al. Coagulation disorders and tumor markers in the diagnosis of pancreatic cancer. Oncology 1991; 48: 377-82.
234. Firpo MA, Gay DZ, Granger SR, et al. Improved Diagnosis of Pancreatic Adenocarcinoma Using Haptoglobin and Serum Amyloid A in a Panel Screen. World J Surgery 2009; 33: 716-22.
235. Bloomston M, Zhou JX, Rosemurgy AS, Frankel W, Muro-Cacho CA, Yeatman TJ. Fibrinogen gamma overexpression in pancreatic cancer identified by large-scale proteomic analysis of serum samples. Cancer Res 2006; 66: 2592-9.
236. Ni XG, Bai XF, Mao YL, et al. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer. Eur J Surg Oncol 2005; 31: 164-9.
237. Dive C, Smith RA, Garner E, et al. Considerations for the use of plasma cytokeratin 18 as a biomarker in pancreatic cancer. British J Cancer 2010; 102: 577-82.
238. Zhou J, Hu L, Yu Z, et al. Marker Expression in Circulating Cancer Cells of Pancreatic Cancer Patients. J Surg Res 2011; 171:631-6.
239. Sabbaghian MS, Rothberger G, Alongi AP, et al. Levels of Elevated Circulating Endothelial Cell Decline after Tumor Resection in Patients with Pancreatic Ductal Adenocarcinoma. Anticancer Res 2010; 30: 2911-7.
240. Lu X, Xu T, Qian J, Wen X, Wu D. Detecting K-ras and p53 gene mutation from stool and pancreatic juice for diagnosis of early pancreatic cancer. Chin Med J (Engl) 2002; 115: 1632-6.
241. Jiao L, Zhu J, Hassan MM, Evans DB, Abbruzzese JL, Li D. K-ras mutation and p16 and preproenkephalin promoter hypermethylation in plasma DNA of pancreatic cancer patients: in relation to cigarette smoking. Pancreas 2007; 34: 55-62.
242. Salek C, Minarikova P, Benesova L, et al. Mutation status of K-ras, p53 and allelic losses at 9p and 18q are not prognostic markers in patients with pancreatic cancer. Anticancer Res 2009; 29: 1803-10.
243. Ghaneh P, Kawesha A, Evans JD, Neoptolemos JP. Molecular prognostic markers in pancreatic cancer. J Hepatobiliary Pancreat Surg 2002; 9: 1-11.
244. Huang L, Goodrow TL, Zhang SY, Klein-Szanto AJ, Chang H, Ruggeri BA. Deletion and mutation analyses of the P16/MTS-1 tumor suppressor gene in human ductal pancreatic cancer reveals a higher frequency of abnormalities in tumor-derived cell lines than in primary ductal adenocarcinomas. Cancer Res 1996; 56: 1137-41.
245. Vasen HF, Wasser M, van Mil A, et al. Magnetic Resonance Imaging Surveillance Detects Early-Stage Pancreatic Cancer in Carriers of a p16-Leiden Mutation. Gastroenterology 2011; 140: 850-6.
246. Chen J, Li D, Wei C, et al. Aurora-A and p16 polymorphisms contribute to an earlier age at diagnosis of pancreatic cancer in Caucasians. Clin Cancer Res 2007; 13: 3100-4.
247. Barbera VM, Martin M, Marinoso L, et al. The 18q21 region in colorectal and pancreatic cancer: independent loss of DCC and DPC4 expression. Biochimica Et Biophysica Acta-Molecular Basis of Disease 2000; 1502: 283-96.
248. Parsi MA, Li A, Li CP, Goggins M. DNA methylation alterations in endoscopic retrograde cholangiopancreatography brush samples of patients with suspected pancreaticobiliary disease. Clin Gastroenterol Hepatol 2008; 6: 1270-8.
249. Wang J, Chen J, Chang P, et al. MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease. Cancer Prev Res (Phila) 2009; 2: 807-13.
250. Lee EJ, Gusev Y, Jiang J, et al. Expression profiling identifies microRNA signature in pancreatic cancer. Int J Cancer 2007; 120: 1046-54.
251. Roldo C, Missiaglia E, Hagan JP, et al. MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors are associated with distinctive pathologic features and clinical behavior. J Clin Oncol 2006; 24: 4677-84.
252. Bhatti I, Lee A, James V, et al. Knockdown of microRNA-21 Inhibits Proliferation and Increases Cell Death by Targeting Programmed Cell Death 4 (PDCD4) in Pancreatic Ductal Adenocarcinoma. J Gastrointest Surg 2010; 15: 199-208.
253. Haglund C, Lundin J, Kuusela P, Roberts PJ. CA 242, a new tumour marker for pancreatic cancer: a comparison with CA 19-9, CA 50 and CEA. Br J Cancer 1994; 70: 487-92.
254. Navaglia F, Fogar P, Basso D, et al. Pancreatic cancer biomarkers discovery by surface-enhanced laser desorption and ionization time-of-flight mass spectrometry. Clin Chem Lab Med 2009; 47: 713-23.
255. Safi F, Roscher R, Beger HG. Tumor markers in pancreatic cancer. Sensitivity and specificity of CA 19-9. Hepatogastroenterology 1989; 36: 419-23.
256. Masson P, Palsson B, Andren-Sandberg A. Cancer-associated tumour markers CA 19-9 and CA-50 in patients with pancreatic cancer with special reference to the Lewis blood cell status. Br J Cancer 1990; 62: 118-21.
257. Ramachandran V, Arumugam T, Wang HM, Logsdon CD. Anterior gradient 2 is expressed and secreted during the development of pancreatic cancer and promotes cancer cell survival. Cancer Res 2008; 68: 7811-8.
258. Allum WH, Stokes HJ, Macdonald F, Fielding JW. Demonstration of carcinoembryonic antigen (CEA) expression in normal, chronically inflamed, and malignant pancreatic tissue by immunohistochemistry. J Clin Pathol 1986; 39: 610-4.
259. Haas M, Laubender RP, Stieber P, et al. Prognostic relevance of CA 19-9, CEA, CRP, and LDH kinetics in patients treated with palliative second-line therapy for advanced pancreatic cancer. Tumor Biology 2010; 31: 351-7.
260. Duraker N, Hot S, Polat Y, Hobek A, Gencler N, Urhan N. CEA, CA 19-9, and CA 125 in the differential diagnosis of benign and malignant pancreatic diseases with or without jaundice. J Surgical Oncol 2007; 95: 142-7.
261. Macdonald F, Downing R, Allum WH. Expression of Ca125 in Pancreatic-Carcinoma and Chronic-Pancreatitis. Br J Cancer 1988; 58: 505-6.
262. Hasholzner U, Stieber P, Reiter W, Zimmermann A, Hofmann K, Schalhorn A. CA 242 in comparison with established tumour markers in colorectal, pancreatic and lung cancer. Anticancer Res 1999; 19: 2477-80.
263. Pasanen PA, Eskelinen M, Partanen K, Pikkarainen P, Penttila I, Alhava E. Receiver operating characteristic (ROC) curve analysis of the tumour markers CEA, CA 50 and CA 242 in pancreatic cancer; results from a prospective study. Br J Cancer 1993; 67: 852-5.
264. Lundin J, Roberts PJ, Kuusela P, Haglund C. Prognostic significance of serum CA 242 in pancreatic cancer. A comparison with CA 19-9. Anticancer Res 1995; 15: 2181-6.
265. Kim J-E, Lee KT, Lee JK, Paik SW, Rhee JC, Choi KW. Clinical usefulness of carbohydrate antigen 19-9 as a screening test for pancreatic cancer in an asymptomatic population. J Gastroenterology and Hepatology 2004; 19: 182-6.
266. Lee MX, Saif MW. Screening for early pancreatic ductal adenocarcinoma: an urgent call! JOP 2009; 10: 104-8.
267. Cwik G, Wallner G, Skoczylas T, Ciechanski A, Zinkiewicz K. Cancer antigens 19-9 and 125 in the differential diagnosis of pancreatic mass lesions. Arch Surg 2006; 141: 968-73; discussion 74.
268. Banfi G, Zerbi A, Pastori S, Parolini D, Dicarlo V, Bonini P. Behavior of Tumor-Markers Ca19.9, Ca195, Cam43, Ca242, and Tps in the Diagnosis and Follow-up of Pancreatic-Cancer. Clinical Chem 1993; 39: 420-3.
269. Jiang XT, Tao HQ, Zou SC. Detection of serum tumor markers in the diagnosis and treatment of patients with pancreatic cancer. Hepatobiliary Pancreat Dis Int 2004; 3: 464-8.